Abstract
Compounds with different sets of three of the four functional groups of (1R,2R,6S)-3-methyl-6-(prop-1-en-2- yl)cyclohex-3-ene-1,2-diol 1 possessing high antiparkinsonian activity were synthesized. The synthesized compounds were tested for the antiparkinsonian activity in vivo on a mouse model with MPTP neurotoxin. A pronounced antiparkinsonian effect of 1 can only be achieved if it contains all the four functional groups (two hydroxy groups and two double bonds). The 2-hydroxy group or the 3,4-double bond is not required for stimulating the exploratory activity of the animals.
Keywords: Antiparkinsonian activity, functional groups, (1R, 2R, 6S)-3-methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1, 2-diol, mice, MPTP model.
Medicinal Chemistry
Title:3-Methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1,2-diol: the Importance of Functional Groups for Antiparkinsonian Activity
Volume: 9 Issue: 5
Author(s): Oleg V. Ardashov, Alla V. Pavlova, Dina V. Korchagina, Konstantin P. Volcho, Tat’ yana G. Tolstikova and Nariman F. Salakhutdinov
Affiliation:
Keywords: Antiparkinsonian activity, functional groups, (1R, 2R, 6S)-3-methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1, 2-diol, mice, MPTP model.
Abstract: Compounds with different sets of three of the four functional groups of (1R,2R,6S)-3-methyl-6-(prop-1-en-2- yl)cyclohex-3-ene-1,2-diol 1 possessing high antiparkinsonian activity were synthesized. The synthesized compounds were tested for the antiparkinsonian activity in vivo on a mouse model with MPTP neurotoxin. A pronounced antiparkinsonian effect of 1 can only be achieved if it contains all the four functional groups (two hydroxy groups and two double bonds). The 2-hydroxy group or the 3,4-double bond is not required for stimulating the exploratory activity of the animals.
Export Options
About this article
Cite this article as:
Ardashov V. Oleg, Pavlova V. Alla, Korchagina V. Dina, Volcho P. Konstantin, Tolstikova G. Tat’ yana and Salakhutdinov F. Nariman, 3-Methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1,2-diol: the Importance of Functional Groups for Antiparkinsonian Activity, Medicinal Chemistry 2013; 9 (5) . https://dx.doi.org/10.2174/1573406411309050013
DOI https://dx.doi.org/10.2174/1573406411309050013 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Tardive Dyskinesia with Atypical Antipsychotic Drugs
Current Drug Therapy Late Life Depression: A Diagnostic and Pharmacological Review
Current Psychopharmacology The Use of Bifunctional NOP/Mu and NOP Receptor Selective Compounds for the Treatment of Pain, Drug Abuse, and Psychiatric Disorders
Current Pharmaceutical Design Neuropeptide Systems and Schizophrenia
CNS & Neurological Disorders - Drug Targets Current Status of Antipsychotic Treatment
Current Drug Targets - CNS & Neurological Disorders Drugs Used to Treat Parkinsons Disease, Present Status and Future Directions
CNS & Neurological Disorders - Drug Targets Clinical Pharmacology of Serotonin Receptor Type 3 (5-HT3) Antagonists
Current Medicinal Chemistry - Central Nervous System Agents Innovations to Control the Environment for Persons with Movement Disorders: Support in Home Care
Recent Patents on Biomedical Engineering (Discontinued) Treatment of Parkinson’s Disease by MAO-B Inhibitors, New Therapies and Future Challenges - A Mini-Review
Combinatorial Chemistry & High Throughput Screening Controversies of Dopamine Agonists: Somnolence, Cardiac Valvulopathy and Repetitive Behaviors
Current Drug Therapy Modulation of Monoaminergic Transporters by Choline-Containing Phospholipids in Rat Brain
CNS & Neurological Disorders - Drug Targets Antipsychotic-like Effects of Cannabidiol and Rimonabant: Systematic Review of Animal and Human Studies
Current Pharmaceutical Design Side Effects of Clozapine and Some Other Psychoactive Drugs
Current Drug Safety Impulse Control Disorders in Parkinson’s Disease: A Review
Current Psychiatry Reviews Clinical Values of Nitric Oxide Parameters from the Respiratory System
Current Medicinal Chemistry Measurement of Physical Changes in the Myocardium for Development of Novel Methods for Diagnosing Ischemia
Current Cardiology Reviews Neuroferritinopathy: Update on Clinical Features and Pathogenesis
Current Drug Targets Systemic Redox Biomarkers in Neurodegenerative Diseases
Current Drug Metabolism Tetrahydrobioterin (BH4) Pathway: From Metabolism to Neuropsychiatry
Current Neuropharmacology 5-HT2 Receptors
Current Drug Targets - CNS & Neurological Disorders